Aeterna Zentaris(AEZS) Newsfilter·2024-08-06 22:00Company Overview - COSCIENS Biopharma Inc. is a specialty biopharmaceutical company focused on developing and commercializing a diverse portfolio of pharmaceutical and diagnostic products for healthcare and cosmetics industries [4] - The company has a lead product, macimorelin (Macrilen; Ghryvelin), which is the first and only FDA and European Commission approved oral test for diagnosing adult growth hormone deficiency [4] Name Change Announcement - The company has officially changed its name from Aeterna Zentaris Inc. to COSCIENS Biopharma Inc. effective August 6, 2024 [1] - The common shares will begin trading under the new symbol "CSCI" on the Toronto Stock Exchange and NASDAQ effective August 9, 2024, ceasing to trade under the former symbol "AEZS" [1][2] Shareholder Information - The name change was approved by shareholders at the annual general and special meeting held on July 16, 2024, and is subject to final approval from TSX and NASDAQ [2] - There will be no change in the company's capitalization, and existing shareholders or warrantholders will not need to take any action regarding the name change [2] New Identifiers - The new CUSIP number for the common shares is 22112H101, and the new ISIN is CA22112H1010 [3] - The new CUSIP number for the warrants is 22112H119, and the new ISIN for the warrants is CA22112H1192 [3]